Han Qu You from Shanghai Fosun Pharmaceutical Co. - trastuzumab biosimilar targets HER2-positive cancer

Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-30, 06:27. Details in the imprint.

Han Qu You from Shanghai Fosun Pharmaceutical Co. is not the kind of drug you notice on a shelf, but oncologists feel its weight when they hang the clear bag on the IV stand and watch the slow drip into a patient’s arm. It is Fosun Pharma’s trastuzumab biosimilar, designed for HER2-positive breast and gastric cancer, and it pushes into a space long dominated by Roche’s Herceptin. In Chinese oncology wards, it is meant to make targeted therapy more accessible without discarding established clinical standards.

What Han Qu You is

Han Qu You is a monoclonal antibody that binds to the HER2 receptor on cancer cells, aiming to slow growth and improve survival in HER2-overexpressing tumors. It mirrors the mechanism of trastuzumab originators, but as a biosimilar it undergoes strict comparability testing rather than full novel-drug development. Fosun Pharma positions the product for both early and advanced stages of breast cancer as well as HER2-positive gastric cancer in its home market.

The drug is administered intravenously, typically after a loading dose followed by maintenance infusions at regular intervals. For patients, that means returning to the infusion chair every few weeks, hearing the quiet hiss of the pump and feeling the chill of the saline line against the skin. Clinical regimens often combine trastuzumab with chemotherapy agents, so Han Qu You is part of a broader cocktail rather than a standalone solution.

Regulatory path and quality claims

Fosun Pharma developed Han Qu You to meet Chinese regulatory requirements for biosimilars, which focus on demonstrating similarity in structure, efficacy and safety to the reference trastuzumab. That involves head-to-head clinical trials and analytical testing to show that any differences are not clinically meaningful for patients. In oncology, regulators are cautious, so manufacturers must be able to present convincing pharmacokinetic and immunogenicity data.

On the manufacturing side, Han Qu You relies on cell-culture processes that have to stay stable across batches, as any drift can affect the antibody’s glycosylation pattern and potentially its activity. Engineers at Fosun Pharma adjust bioreactor conditions obsessively, watching dissolved oxygen, pH and cell density readings in real time. The company communicates that its biologics facilities are designed to meet international good manufacturing practice standards, aiming to reassure physicians who are wary of switching from originator brands.

How it changes daily practice

For oncologists such as Dr. Li Wei in Shanghai, Han Qu You adds another trastuzumab label to a prescribing screen that already includes international brands. He weighs factors like hospital procurement price, patient insurance coverage and the comfort level of his nursing staff with different infusion protocols. When patients ask whether a domestic biosimilar is as good as the imported drug, he reaches for data, not slogans.

From the patient’s perspective, the experience of receiving Han Qu You is almost indistinguishable from receiving the originator. The nurse checks identity, premedication, then opens the clamp and watches for early reactions. Some patients feel a quiet fatigue settle in during the drip, others watch dramas on a phone balanced on the blanket. The brand name on the bag matters financially and emotionally, but the lived sensory experience is mostly the hum of air conditioning and the soft beeping of monitors.

Pricing, access and competition

In China’s public hospital system, pricing for drugs like Han Qu You is shaped by provincial tender processes and negotiations with national reimbursement schemes. Biosimilars are often positioned at a discount to imported originators, hoping to win formulary inclusion and broader access. For families tracking bills, the difference can decide whether a full course of therapy is financially sustainable.

At the same time, Fosun Pharma has to balance lower per-unit pricing with volume and manufacturing efficiency. Biologics plants are capital-intensive; once built, they need capacity utilization to pay off. Competitive pressure also comes from other domestic biosimilar developers, all targeting the same HER2 space. On procurement lists, Han Qu You is one name among several, and purchasing managers scrutinize not only price but supply reliability and post-marketing safety data.

Where it fits in Fosun’s strategy

Executive chairman Chen Qiyu has repeatedly framed Fosun Pharma’s strategy around innovation and globalization, with biologics and biosimilars as core growth pillars. Han Qu You shows that ambition at the product level, turning abstract strategy slides into something tangible hanging on an infusion rack. As more originator biologics lose exclusivity, the company wants a pipeline ready to move.

Han Qu You also illustrates Fosun Pharma’s move up the value chain from traditional generics toward complex biologics. That shift changes the skills required internally: more bioprocess engineers, more clinical-development specialists and tighter pharmacovigilance operations. It moves the company into closer competition with multinational pharmas, not only on price but on technology and credibility in global regulatory conversations.

Stock context and trading venue

Net-net, Han Qu You is a clinical product first and a financial story second, but it feeds the narrative of Shanghai Fosun Pharmaceutical as a biologics-heavy player in China’s oncology market. Shanghai Fosun Pharmaceutical shares (ISIN CNE100000536) trade primarily in Hong Kong and Shanghai, and investors watch biologics launches like Han Qu You as indicators of long-term revenue mix rather than short-term trading catalysts.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | CNE100000536 | FOSUN PHARMA | boerse | 69656963 | bgmi